FDA grants Fast Track designation to Bbo-11818 for KRAS-mutated pancreatic cancer
BridgeBio Oncology Therapeutics said Bbo-11818 received FDA Fast Track designation for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma. The status may accelerate development and review and allow more frequent FDA communication during clinical trials.
BridgeBio Oncology Therapeutics, Inc. announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administration. This designation will accelerate the development and review process of the candidate drug, bringing new treatment hope to patient groups with urgent unmet medical needs.
As the most common type of pancreatic cancer, KRAS-mutant pancreatic ductal adenocarcinoma has long lacked effective targeted therapy options. Obtaining Fast Track designation demonstrates the therapeutic potential Bbo-11818 has shown in early research and means the drug can benefit from more frequent communication with the FDA during subsequent clinical trials, potentially expediting its progress to the marketing application stage.